ATE430555T1 - Pharmazeutische zusammensetzungen zur behandlung von asthma - Google Patents

Pharmazeutische zusammensetzungen zur behandlung von asthma

Info

Publication number
ATE430555T1
ATE430555T1 AT02753549T AT02753549T ATE430555T1 AT E430555 T1 ATE430555 T1 AT E430555T1 AT 02753549 T AT02753549 T AT 02753549T AT 02753549 T AT02753549 T AT 02753549T AT E430555 T1 ATE430555 T1 AT E430555T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
treating asthma
asthma
treating
pharmaceutical
Prior art date
Application number
AT02753549T
Other languages
German (de)
English (en)
Inventor
Joel Sequeira
Stefan Sharpe
John Hart
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23224164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE430555(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE430555T1 publication Critical patent/ATE430555T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02753549T 2001-08-28 2002-08-27 Pharmazeutische zusammensetzungen zur behandlung von asthma ATE430555T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31538601P 2001-08-28 2001-08-28
PCT/US2002/027336 WO2003020253A2 (en) 2001-08-28 2002-08-27 Pharmaceutical compositions for the treatment of asthma

Publications (1)

Publication Number Publication Date
ATE430555T1 true ATE430555T1 (de) 2009-05-15

Family

ID=23224164

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02753549T ATE430555T1 (de) 2001-08-28 2002-08-27 Pharmazeutische zusammensetzungen zur behandlung von asthma
AT09006110T ATE503461T1 (de) 2001-08-28 2002-08-27 Pharmazeutische zusammensetzungen zur behandlung von asthma

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT09006110T ATE503461T1 (de) 2001-08-28 2002-08-27 Pharmazeutische zusammensetzungen zur behandlung von asthma

Country Status (26)

Country Link
US (3) US20030114428A1 (enExample)
EP (3) EP2319494B1 (enExample)
JP (3) JP2005502675A (enExample)
KR (1) KR100970531B1 (enExample)
CN (2) CN101856362A (enExample)
AR (1) AR036358A1 (enExample)
AT (2) ATE430555T1 (enExample)
AU (1) AU2002313828B2 (enExample)
BR (1) BR0212089A (enExample)
CA (1) CA2457926A1 (enExample)
CO (1) CO5560551A2 (enExample)
CY (2) CY1109212T1 (enExample)
DE (2) DE60239648D1 (enExample)
DK (2) DK2092935T3 (enExample)
ES (3) ES2389480T3 (enExample)
HU (1) HUP0401514A3 (enExample)
MX (1) MXPA04001875A (enExample)
NO (1) NO20041277L (enExample)
NZ (1) NZ530987A (enExample)
PE (1) PE20030390A1 (enExample)
PL (1) PL209640B1 (enExample)
PT (2) PT2092935E (enExample)
SI (2) SI2092935T1 (enExample)
TW (1) TWI324934B (enExample)
WO (1) WO2003020253A2 (enExample)
ZA (1) ZA200401419B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
EP1785156B1 (en) * 2002-08-23 2012-06-27 Schering Corporation Metered dose inhaler containing an aerosol suspension formulation
JP2005536538A (ja) * 2002-08-23 2005-12-02 シェーリング　コーポレイション 薬学的組成物
MXPA05002248A (es) * 2002-08-27 2005-06-08 Schering Corp Procedimiento para producir formulaciones de inhalador de dosis medida.
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
EP1925293A3 (en) * 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
KR20060106823A (ko) * 2003-10-20 2006-10-12 쉐링 코포레이션 약제학적 에어로졸 조성물
EP1711164B1 (en) * 2004-01-21 2010-03-24 Schering Corporation Method of treating acute rhinosinusitis
US20110053999A1 (en) 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
CA2581999C (en) * 2004-10-12 2013-04-23 Generics (Uk) Limited Preparation of suspension aerosol formulations
EP2484382A1 (en) 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
CA2641616A1 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
EP2117504A1 (en) * 2007-02-09 2009-11-18 Schering Corporation Stable pharmaceutical drug aerosols
GB0714239D0 (en) * 2007-07-20 2007-08-29 Glaxo Group Ltd Method
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
MX2010007569A (es) * 2008-01-10 2011-03-21 Schering Corp Star Productos farmaceuticos para inhalacion, sistemas y usos.
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
US9265910B2 (en) 2009-05-18 2016-02-23 Boehringer Ingelheim International Gmbh Adapter, inhalation device, and nebulizer
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TWI792140B (zh) * 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
WO2011027247A1 (en) 2009-09-03 2011-03-10 Sulur Subramaniam Vanangamudi An antifungal cream comprising terbinafine hydrochloride
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
AP3141A (en) 2009-11-25 2015-02-28 Boehringer Ingelheim Int Nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
WO2011064163A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
SG10201710156RA (en) * 2009-12-07 2018-01-30 Raptor Therapeutics Inc 4-methylpyrazole formulations
WO2011101830A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and clobetasone, and a process to make it
WO2011101828A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sidium fusidate and incorporating a biopolymer and betamethasone, and a process to make it
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
WO2012017368A1 (en) 2010-08-02 2012-02-09 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, beclomethasone dipropionate and a process to make it
WO2012049543A1 (en) 2010-10-15 2012-04-19 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a corticosteroid, and a process to make it
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
CN103874483B (zh) 2011-10-11 2017-09-12 奇斯药制品公司 包衣了脂肪酸的β‑激动剂的晶体微粒
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
JP6643231B2 (ja) 2013-08-09 2020-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
EP2835146B1 (en) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Nebulizer
CN106456913B (zh) 2014-05-07 2019-08-30 勃林格殷格翰国际有限公司 喷雾器和容器
EP3139984B1 (en) 2014-05-07 2021-04-28 Boehringer Ingelheim International GmbH Nebulizer
DK3139979T3 (da) 2014-05-07 2023-10-09 Boehringer Ingelheim Int Enhed, forstøver og fremgangsmåde
ES2952510T3 (es) 2014-06-30 2023-10-31 Proveris Scient Corporation Aparato de muestreo para determinar la cantidad y uniformidad de una dosis administrada de medicamento y métodos relacionados
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
ES2796177T5 (es) 2015-12-04 2024-10-29 Mexichem Fluor Sa De Cv Composición farmacéutica
CA3016890A1 (en) * 2016-03-09 2017-09-14 Proveris Scientific Corporation Methods for measuring dose content uniformity performance of inhaler and nasal devices
CN106619658B (zh) * 2016-12-28 2022-02-08 四川普锐特药业有限公司 一种医用气溶胶制剂及定量吸入气雾剂
WO2021219495A1 (en) 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SK140493A3 (en) * 1991-06-10 1994-10-05 Schering Corp Non-chlorofluorocarbon aerosol formulations
US6250300B1 (en) * 1992-12-11 2001-06-26 Ab Astra System for dispensing pharmaceutically active compounds
DE69530325T2 (de) * 1994-12-22 2004-02-19 Astrazeneca Ab Aerosol-arzneiformulierungen
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
CZ294064B6 (cs) * 1996-08-29 2004-09-15 Schering Corporation Aerosolový suspenzní přípravek mometazonfuroátu bez chlorfluorovaných uhlovodíků
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
TW533865U (en) * 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
EP1133301A1 (en) * 1998-11-26 2001-09-19 Britannia Pharmaceuticals Limited Anti-asthmatic combinations comprising surface active phospholipids
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
ES2220724T3 (es) * 2000-01-20 2004-12-16 Basilea Pharmaceutica Ag Composiciones de peptidos ciclicos administrables por via nasal.
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme

Also Published As

Publication number Publication date
TWI324934B (en) 2010-05-21
EP1420759B1 (en) 2009-05-06
DK2092935T3 (da) 2011-07-18
PE20030390A1 (es) 2003-04-24
CN1649568B (zh) 2010-10-27
SI1420759T1 (sl) 2009-10-31
EP1420759A2 (en) 2004-05-26
WO2003020253A3 (en) 2003-05-22
HUP0401514A3 (en) 2012-08-28
NO20041277L (no) 2004-03-26
CN101856362A (zh) 2010-10-13
CA2457926A1 (en) 2003-03-13
CN1649568A (zh) 2005-08-03
MXPA04001875A (es) 2004-06-15
KR100970531B1 (ko) 2010-07-16
ES2389480T3 (es) 2012-10-26
NZ530987A (en) 2006-08-31
DK1420759T3 (da) 2009-08-03
CY1109212T1 (el) 2014-07-02
BR0212089A (pt) 2004-08-03
JP2009185075A (ja) 2009-08-20
CY1111726T1 (el) 2015-10-07
JP2010138184A (ja) 2010-06-24
AR036358A1 (es) 2004-09-01
EP2092935A1 (en) 2009-08-26
ZA200401419B (en) 2005-01-26
US20050147565A1 (en) 2005-07-07
PT2092935E (pt) 2011-05-31
US20100143269A1 (en) 2010-06-10
HUP0401514A2 (hu) 2004-12-28
ATE503461T1 (de) 2011-04-15
ES2325316T3 (es) 2009-09-01
JP2005502675A (ja) 2005-01-27
KR20040031002A (ko) 2004-04-09
US20030114428A1 (en) 2003-06-19
DE60232251D1 (de) 2009-06-18
HK1128428A1 (en) 2009-10-30
EP2319494B1 (en) 2012-06-13
JP5170789B2 (ja) 2013-03-27
CO5560551A2 (es) 2005-09-30
ES2361805T3 (es) 2011-06-22
PL209640B1 (pl) 2011-09-30
HK1151987A1 (en) 2012-02-17
EP2092935B1 (en) 2011-03-30
AU2002313828B2 (en) 2005-09-08
PL368897A1 (en) 2005-04-04
PT1420759E (pt) 2009-06-30
SI2092935T1 (sl) 2011-07-29
EP2319494A1 (en) 2011-05-11
DE60239648D1 (de) 2011-05-12
HK1060972A1 (en) 2004-09-03
WO2003020253A2 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
ATE503461T1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE60142473D1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
EE200300370A (et) Atsüülitud 6,7,8,9-tetrahüdro-5H-bensotsükloheptenüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
FI20011478A0 (fi) Farmaseuttinen koostumus
EE200300369A (et) Atsüülitud indanüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE602004022036D1 (de) Verfahren zur behandlung von atherosklerose, dyslipidämie und verwandten erkrankungen und pharmazeutische zusammensetzungen
ATE265860T1 (de) Impstoff zur behandlung von atherosclerosis
ATE326842T1 (de) Zusammensetzung zur saatgutbehandlung
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60132600D1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
FI20022128L (fi) Farmaseuttinen koostumus
EP1395215A4 (en) QUINOLONE CARBOXYLIC ACID COMPOSITIONS AND METHODS OF TREATMENT THEREOF
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE60218375D1 (de) Pharmazeutische Zusammensetzung zur Behandlung gynäkologischer Erkrankungen
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
ATE274044T1 (de) Zusammensetzungen zur behandlung von gewebe

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1420759

Country of ref document: EP